Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2022-05-09 00:00:00 ET · period of report 2022-04-29 · accession 0001567619-22-009865 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-09 | 2022-05-05+ | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $37.46 | +30.0K | 345.3K | +10% | +$1.12M |
| DM | 2022-05-09 | 2022-05-05+ | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $82.05 | -30.0K | 335.3K | -8% | -$2.46M |
| D | 2022-05-09 | 2022-04-29 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | A - Grant | $62.41 | +341 | 335.3K | +0.1% | +$21.3K |
| DM | 2022-05-09 | 2022-05-05+ | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $0.00 | -30.0K | 20.0K | -60% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-06 | M | A | 20,000 | $37.46 | 355,324 | D | — | — | (F3) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 73% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime. |
| 2 | Common | Common Stock | 2022-05-05 | S | D | 10,000 | $84.14 | 335,324 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. |
| 3 | Common | Common Stock | 2022-05-05 | M | A | 10,000 | $37.46 | 345,324 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. |
| 4 | Common | Common Stock | 2022-04-29 | A | A | 341 | $62.41 | 335,324 | D | — | — | (F1) Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan. |
| 5 | Common | Common Stock | 2022-05-06 | S | D | 20,000 | $81.00 | 335,324 | D | — | — | (F3) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 73% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime. |
| 6 | Derivative | Stock Option (Right to buy Common Stock) | 2022-05-06 | M | D | 20,000 | $0.00 | 0 | D | $37.46 · 2012-11-08 to 2022-05-07 | 20,000 Common Stock | (F3) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 73% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime. (F4) Reflects the number of options outstanding after the transactions from this specific stock option grant. |
| 7 | Derivative | Stock Option (Right to buy Common Stock) | 2022-05-05 | M | D | 10,000 | $0.00 | 20,000 | D | $37.46 · 2012-11-08 to 2022-05-07 | 10,000 Common Stock | (F2) Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. (F4) Reflects the number of options outstanding after the transactions from this specific stock option grant. |